Table 1.
Patient and treatment characteristics. Summary of patient characteristics and details of treatment
| Characteristics | n = 36 | |
|---|---|---|
| Age (years), range (median) | 34-78 (53) | |
| Follow-up period (months), range (median) | 3-83 (39) | |
| FIGO stage (2018) | ||
| IB3 | 1 | |
| IIA2-IIB | 8 | |
| III | 23 | |
| IVA | 4 | |
| Histological sub-types | ||
| Adenocarcinoma | 28 | |
| Adenosquamous carcinoma | 9 | |
| Pelvic LN metastasis | ||
| No | 16 | |
| Yes | 20 | |
| Para-aortic LN metastasis | ||
| No | 30 | |
| Yes | 6 | |
| Tumor size at diagnosis (cm), range (median) | 4.0-14.5 (5.7) | |
| Tumor size before brachytherapy (cm), range (median) | 2.1-10.3 (4.1) | |
| Overall treatment time (days), range (median) | 38-69 (48) | |
| Concurrent chemotherapy administrations | ||
| No | 7 | |
| Yes | 29 | |
| EBRT strategy | ||
| 3D-CRT, WP + CS | 30 | |
| 3D-CRT, WP alone | 4 | |
| IMRT | 2 | |
| EBRT, EQD2 (Gy), range (median) | ||
| EQD2 (α/β = 10) | 26.0-53.1 (30.1) | |
| EQD2 (α/β = 3) | 26.0-51.8 (30.0) | |
| 3D-IGBT strategy | ||
| Typical 3D-IGBT | 15 | |
| 3D-IGBT with interstitial (hybrid) | 21 | |
| Number of 3D-IGBT sessions | ||
| 3 sessions | 1 | |
| 4 sessions | 25 | |
| 5 sessions | 9 | |
| 6 sessions | 1 | |
| 3D-IGBT, EQD2 (α/β = 10) (Gy), range (median) | ||
| HR-CTV D90 | 15.6-54.2 (40.6) | |
| 3D-IGBT, EQD2 (α/β = 3) (Gy), range (median) | ||
| Rectum D2cc (median) | 8.8-36.9 (25.5) | |
| Bladder D2cc (median) | 14.0-62.4 (39.3) | |
| WP + 3D-IGBT, EQD2 (α/β = 10) (Gy), range (median)1 | ||
| HR-CTV D90 | 54.9-96.1 (74.7) | |
| WP + 3D-IGBT, EQD2 (α/β = 3) (Gy), range (median)1 | ||
| Rectum D2cc (median) | 41.2-79.5 (60.8) | |
| Bladder D2cc (median) | 57.2-94.8 (73.1) | |
FIGO – International Federation of Gynecology and Obstetrics; LN – lymph node; EBRT – external beam radiotherapy; 3D-CRT – three dimensional-conformal radiation therapy; WP – whole pelvic irradiation; CS – central shielding; IMRT – intensity-modulated radiotherapy; EQD2 – equivalent dose of 2 Gy per fraction; 3D-IGBT – three-dimensional image-guided brachytherapy; HR-CTV – high-risk clinical target volume; D90 – dose to 90% of target volume; D2cc – minimum dose delivered to the highest irradiated two cc area; 1 due to the difficulty of accurate evaluation, the doses of pelvic irradiation with CS were not added to the EQD2